Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

Journal of Leukocyte Biology
Early View

ARTICLE - COVID-19 AND RELATED TOPICS

VIP plasma levels associate with survival in severe COVID-19 patients, correlating with protective effects in SARS-CoV-2-infected cells
…
First published: 24 March 2022
https://doi.org/10.1002/JLB.5COVA1121-626R
.
.
.
Our findings support and encourage clinical trials with VIP in COVID-19 patients, which are in progress with intravenous 38 and inhaled 39, 40 formulations and are expected to be disclosed throughout this year. An initial release of the data, as preprint, shows an increase in survival rates and reduction of IL-6 levels on those who received intravenous AVIPTADIL (VIP) 62. Our present data may substantiate additional larger trials with VIP, an overlooked molecule associated with antiviral, anti-inflammatory, and enhanced survival activities.

https://jlb.onlinelibrary.wiley.com/doi/10.1002/JLB.5COVA1121-626R

~ posted by IG, Y@h00 RLFTF finance conversations

Did the FDA know about crimes of extraordinary scale???

https://rumble.com/vx6yvt-161-lawyers-working-on-pfizers-crimes-of-extraordinary-scale.html